Interim report January 1-June 30, 2015: Financially stable - new investments in regenerative medicine: CDNF and Lymfactin
Interim report January 1-June 30, 2015 (unaudited) Highlights in January-June 2015: · Tekes, the Finnish Funding Agency for Innovation, granted a 2,903 million euro R&D loan to the company to support its clinical study of CDNF for the treatment of Parkinson's disease. Clinical trial applications will be submitted in 2015. · Initial results of the Phase 2 study of cis-UCA Eye Drops did not meet expectations. Cis-UCA Eye Drop was statistically significantly better than placebo in only certain secondary endpoints. The company writes off the remaining activated development expenses